NasdaqGS - Delayed Quote • USD
Grifols, S.A. (GRFS)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 7 | 6 |
| Avg. Estimate | 0.16 | 0.23 | 0.93 | 1.28 |
| Low Estimate | 0.16 | 0.23 | 0.75 | 0.95 |
| High Estimate | 0.16 | 0.23 | 1.39 | 1.81 |
| Year Ago EPS | 0.04 | 0.15 | 0.39 | 0.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 2 | 8 | 7 |
| Avg. Estimate | 1.78B | 4.71B | 7.56B | 8.12B |
| Low Estimate | 1.78B | 1.93B | 7.15B | 7.71B |
| High Estimate | 1.78B | 7.5B | 7.95B | 8.64B |
| Year Ago Sales | 1.7B | 1.81B | 7.06B | 7.56B |
| Sales Growth (year/est) | 4.90% | 160.30% | 7.20% | 7.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.22 | 0.18 | 0.24 | 0.24 |
| EPS Actual | 0.04 | 0.15 | 0.12 | 0.15 |
| Difference | -0.18 | -0.03 | -0.12 | -0.09 |
| Surprise % | -81.80% | -16.70% | -50.00% | -37.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.16 | 0.23 | 0.93 | 1.28 |
| 7 Days Ago | 0.16 | 0.23 | 0.85 | 1.17 |
| 30 Days Ago | 0.16 | 0.23 | 0.87 | 1.24 |
| 60 Days Ago | 0 | 0 | 1.01 | 1.35 |
| 90 Days Ago | 0 | 0 | 1.02 | 1.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GRFS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 300.00% | -- | -- | 2.60% |
| Next Qtr. | 53.30% | -- | -- | 13.40% |
| Current Year | 138.50% | -- | -- | 5.20% |
| Next Year | 37.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 34.68% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -20.29% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | Deutsche Bank: Hold to Sell | 3/12/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 12/5/2023 |
| Downgrade | Deutsche Bank: Buy to Hold | 11/5/2021 |
| Upgrade | Credit Suisse: Neutral to Outperform | 3/23/2021 |
| Upgrade | HSBC: Hold to Buy | 3/11/2021 |
| Upgrade | Santander: Hold to Buy | 10/28/2019 |
Related Tickers
SNY Sanofi
49.36
+5.90%
OGN Organon & Co.
18.42
-1.55%
AZN AstraZeneca PLC
75.03
+5.38%
RHHBF Roche Holding AG
273.40
-0.59%
GSK GSK plc
40.91
+0.12%
NVS Novartis AG
99.06
+0.72%
BAYRY Bayer Aktiengesellschaft
7.27
+0.14%
CIPLA.NS Cipla Limited
1,416.15
+0.71%
BIIB Biogen Inc.
202.46
+0.23%
RHHBY Roche Holding AG
30.02
-1.70%